Nagaraj M. Kulkarni

Old Mahabalipuram Road, Sozhanganallur
Chennai, TN 600119, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

STE20-Type Protein Kinase MST4 Controls NAFLD Progression by Regulating Lipid Droplet Dynamics and Metabolic Stress in Hepatocytes.

STE20-Type Protein Kinase MST4 Controls NAFLD Progression by Regulating Lipid Droplet Dynamics and Metabolic Stress in Hepatocytes.

Journal: Hepatology communications

Published: November 11, 2020

Depletion of protein kinase STK25 ameliorates renal lipotoxicity and protects against diabetic kidney disease.

Depletion of protein kinase STK25 ameliorates renal lipotoxicity and protects against diabetic kidney disease.

Journal: JCI insight

Published: May 20, 2020

Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.

Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.

Journal: Cellular and molecular gastroenterology and hepatology

Published: October 01, 2018

STK25 regulates oxidative capacity and metabolic efficiency in adipose tissue.

STK25 regulates oxidative capacity and metabolic efficiency in adipose tissue.

Journal: The Journal of endocrinology

Published: May 07, 2018

Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.

Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.

Journal: Anti-cancer drugs

Published: July 21, 2017

Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease.

Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease.

Journal: Drug metabolism and personalized therapy

Published: April 04, 2016

Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.

Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.

Journal: European journal of pharmacology

Published: June 02, 2015

A novel animal model of metabolic syndrome with non-alcoholic fatty liver disease and skin inflammation.

A novel animal model of metabolic syndrome with non-alcoholic fatty liver disease and skin inflammation.

Journal: Pharmaceutical biology

Published: November 29, 2014

Topical atorvastatin ameliorates 12-O-tetradecanoylphorbol-13-acetate induced skin inflammation by reducing cutaneous cytokine levels and NF-κB activation.

Topical atorvastatin ameliorates 12-O-tetradecanoylphorbol-13-acetate induced skin inflammation by reducing cutaneous cytokine levels and NF-κB activation.

Journal: Archives of pharmacal research

Published: May 29, 2014

Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL/6 mice.

Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL/6 mice.

Journal: Indian journal of pharmacology

Published: January 03, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026